Associations of common genetic risk variants of the muscarinic acetylcholine receptor M2 with cardiac autonomic dysfunction in patients with schizophrenia

World J Biol Psychiatry. 2023 Jan;24(1):1-11. doi: 10.1080/15622975.2022.2043561. Epub 2022 Mar 9.

Abstract

Objectives: Decreased vagal modulation, which has consistently been observed in schizophrenic patients, might contribute to increased cardiac mortality in schizophrenia. Previously, associations between CHRM2 (Cholinergic Receptor Muscarinic 2) and cardiac autonomic features have been reported. Here, we tested for possible associations between these polymorphisms and heart rate variability in patients with schizophrenia.

Methods: A total of three single nucleotide polymorphisms (SNPs) in CHRM2 (rs73158705 A>G, rs8191992 T>A and rs2350782 T>C) that achieved significance (p < 5 * 10-8) in genome-wide association studies for cardiac autonomic features were genotyped in 88 drug-naïve patients, 61 patients receiving antipsychotic medication and 144 healthy controls. Genotypes were analysed for associations with parameters of heart rate variability and complexity, in each diagnostic group.

Results: We observed a significantly altered heart rate variability in unmedicated patients with identified genetic risk status in rs73158705 A>G, rs8191992 T>A and rs2350782 T>C as compared to genotype non-risk status. In patients receiving antipsychotic medication and healthy controls, these associations were not observed.

Discussion: We report novel candidate genetic associations with cardiac autonomic dysfunction in schizophrenia, but larger cohorts are required for replication.

Keywords: CHRM2; Schizophrenia; autonomic dysfunction; cardiac mortality; heart rate variability; vagal function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Genome-Wide Association Study
  • Heart Rate / physiology
  • Humans
  • Polymorphism, Single Nucleotide
  • Receptor, Muscarinic M2 / genetics
  • Schizophrenia* / drug therapy
  • Schizophrenia* / genetics

Substances

  • Antipsychotic Agents
  • Receptor, Muscarinic M2